- Home
- BRBR vs TGTX Comparison
BRBR vs TGTX Comparison
Compare BRBR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRBR
- TGTX
- Stock Information
- Founded
- BRBR 2019
- TGTX 1993
- Country
- BRBR United States
- TGTX United States
- Employees
- BRBR N/A
- TGTX N/A
- Industry
- BRBR Packaged Foods
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- BRBR Consumer Staples
- TGTX Health Care
- Exchange
- BRBR Nasdaq
- TGTX Nasdaq
- Market Cap
- BRBR 4.5B
- TGTX 5.1B
- IPO Year
- BRBR 2019
- TGTX 1995
- Fundamental
- Price
- BRBR $34.29
- TGTX $34.09
- Analyst Decision
- BRBR Buy
- TGTX Strong Buy
- Analyst Count
- BRBR 17
- TGTX 6
- Target Price
- BRBR $65.76
- TGTX $47.50
- AVG Volume (30 Days)
- BRBR 2.5M
- TGTX 1.9M
- Earning Date
- BRBR 11-17-2025
- TGTX 11-03-2025
- Dividend Yield
- BRBR N/A
- TGTX N/A
- EPS Growth
- BRBR 5.53
- TGTX N/A
- EPS
- BRBR 1.75
- TGTX 0.36
- Revenue
- BRBR $2,224,200,000.00
- TGTX $454,069,000.00
- Revenue This Year
- BRBR $17.62
- TGTX $82.22
- Revenue Next Year
- BRBR $9.80
- TGTX $47.76
- P/E Ratio
- BRBR $19.48
- TGTX $93.58
- Revenue Growth
- BRBR 16.27
- TGTX 30.96
- 52 Week Low
- BRBR $33.73
- TGTX $21.27
- 52 Week High
- BRBR $80.67
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- BRBR 35.48
- TGTX 53.72
- Support Level
- BRBR $33.73
- TGTX $33.10
- Resistance Level
- BRBR $35.51
- TGTX $37.45
- Average True Range (ATR)
- BRBR 1.09
- TGTX 1.20
- MACD
- BRBR 0.11
- TGTX -0.02
- Stochastic Oscillator
- BRBR 21.36
- TGTX 39.11
About BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channels including club, food, drug and mass, eCommerce, convenience and specialty.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.